Lineage Cell Therapeutics (LCTX) Other Non-Current Assets (2010 - 2023)

Lineage Cell Therapeutics' Other Non-Current Assets history runs 14 years deep, the most recent figure standing at $552000.0 for Q3 2023.

• On a quarterly basis, Other Non-Current Assets fell 6.6% year-over-year to $552000.0 in Q3 2023; TTM through Sep 2023 was $552000.0, a 6.6% decrease from a year earlier, with the FY2022 full-year figure at $627000.0, changed 0.48% from the prior year.
• Other Non-Current Assets retreated to $552000.0 in Q3 2023 per LCTX's latest filing, from $588000.0 in the prior quarter.
• Across five years, Other Non-Current Assets topped out at $890000.0 in Q1 2019 and bottomed at $515000.0 in Q2 2021.
• The 5-year median for Other Non-Current Assets is $614000.0 (2021), against an average of $637526.3.
• Across the five-year window, Other Non-Current Assets jumped 277.12% in 2019 and slumped 37.42% in 2020, its largest moves.
• Year by year, Other Non-Current Assets stood at $599000.0 in 2019, then climbed by 2.84% to $616000.0 in 2020, then grew by 2.27% to $630000.0 in 2021, then decreased by 0.48% to $627000.0 in 2022, then slipped by 11.96% to $552000.0 in 2023.
• Per Business Quant, the three latest LCTX Other Non-Current Assets figures stand at $552000.0 (Q3 2023), $588000.0 (Q2 2023), and $635000.0 (Q1 2023).